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Abstract
Background: Radiation therapy-related dysphagia is worsened by xerostomia. The submandibular glands (SMG)
produce saliva rich in lubricating mucins, and sparing the SMG has been shown to reduce xerostomia. The goal of
this study was to determine whether SMG sparing IMRT is associated with reduced post-treatment PEG dependence in
locally advanced oropharynx cancer patients.
Methods: Patients treated with definitive radiation therapy for oropharynx cancer were included in this retrospective
study. Those with disease recurrence were excluded. Salivary glands and swallowing-related organs at risk, including
pharyngeal constrictors, were contoured. Primary endpoint was time from end of radiation treatment to freedom from
gastrostomy (PEG) tube dependence. Cox proportional hazards regression and logistic regression were used to assess
influence of normal tissue doses on swallowing related endpoints.
Results: Sixty-nine patients were included. All had stage III/IV disease and 97% received concurrent systemic therapy.
Fifty-seven percent had contralateral SMG (cSMG) mean dose <50 Gy, a level shown to predict for xerostomia. Eighty
four percent of patients had a PEG tube placed electively. On univariate analysis, the strongest predictor of time to
freedom from PEG tube dependence was cSMG dose (HR 0.97 per Gy (95% CI 0.95–0.98), p < 0.0001). This relationship
persisted on multivariate analysis (p = 0.052). The dose to superior and middle pharyngeal constrictor muscles, and
larynx were also significant on univariate analysis. Patients with cSMG dose less than median (42 Gy, n = 34) had a
significantly shorter time to freedom from PEG dependence: median 1.9 vs. 3.5 months, p < 0.0001. At 6 months, 3%
of patients with cSMG dose < 42 Gy were PEG dependent compared to 31% with cSMG dose > 42 Gy (p = 0.002).
Conclusions: Patients treated with cSMG sparing radiotherapy had significantly shorter time to PEG tube removal after
treatment, suggesting a clinically meaningful reduction in subacute dysphagia compared to non-cSMG sparing
treatment.
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Background
Dysphagia is a common late toxicity of radiation therapy
for head and neck cancer and is detrimental to quality of
life [1, 2]. A variety of risk factors for post-treatment dys-
phagia have been identified, including use of concurrent
chemotherapy, advanced disease stage, and higher dose to
pharyngeal constrictor muscles and other swallowing-re-
lated organs [3–5]. However, retrospective studies
have shown little consistency in which individual
swallowing-related structures are most important, and
some studies failed to show a correlation between
pharyngeal constrictor muscle dose and dysphagia
when controlling for tumor location and other factors
[1, 6, 7]. In a prospective study in oropharynx cancer pa-
tients, even when treatment was planned to minimize
dose to swallowing structures (pharyngeal constric-
tors, larynx, and esophageal inlet), post-treatment
dysphagia was common and persisted years after
treatment [2]. Together, these data indicate a need for
additional strategies to minimize post-treatment
dysphagia.
Another common side effect of head and neck radi-
ation therapy, xerostomia, exacerbates post-treatment
dysphagia. Xerostomia is known to impede the normal
swallowing process, especially for dry foods. In a study of
post-radiation therapy patients with xerostomia, the swal-
lowing steps of mastication and oral manipulation were
compromised for solid foods [8]. Other studies have
shown that post-treatment dysphagia and xerostomia are
highly correlated, for both observer- and patient-reported
measures [9–11]. Therefore, sparing the function of the
salivary glands and reducing xerostomia could be a con-
tributory strategy to reduce treatment-induced dysphagia.
However, studies have not shown a consistent link
between sparing the parotid gland alone and reducing
dysphagia. In the PARSPORT randomized study compar-
ing parotid sparing versus non-salivary sparing radiation
therapy in head and neck cancer patients, late grade 3–4
dysphagia was actually more common in parotid spared
patients at 12 months (9% vs. 5%) [12]. Sparing one or
both submandibular glands (SMG) in addition to sparing
the parotid glands has been shown to further reduce
xerostomia in patients with oropharynx cancer [13, 14].
The SMGs produce saliva rich in mucins that act as a
lubricant during the swallowing process [15]. While stim-
ulated saliva is largely derived from the parotid, the opti-
mal viscosity of the food bolus required for a successful
swallow is also dependent on SMG derived mucinous
saliva [15–18]. The goal of the present study was to deter-
mine whether contralateral submandibular gland (cSMG)
sparing treatment is associated with decreased dur-
ation of PEG (percutaneous endoscopic gastrostomy)




This was a retrospective study approved by the Insti-
tutional Review Board. Eligible patients were treated
at our institution for oropharyngeal squamous cell
carcinoma with definitive IMRT including bilateral
neck treatment. Patients were required to have six
months or longer follow-up in order to assess late
toxicities. Those treated prior to late 2007 were not
eligible because their computerized treatment plans
were no longer accessible. Exclusion criteria included
primary tumor resection prior to radiation therapy,
any disease recurrence after radiation therapy, and
prior radiation therapy to the head and neck region.
Feeding tube placement
Per institutional policy, patients receiving concurrent
chemoradiation had PEG tubes placed prophylactically
prior to starting treatment unless they declined this pro-
cedure. For the patients who received radiation therapy
without chemotherapy a case-by-case determination on
prophylactic vs. as-needed (reactive) placement is made.
After treatment, the feeding tube is removed once the
patient is able to maintain his/her weight for 1–2 weeks
using oral nutrition alone. These policies have not
changed over the study period.
Radiotherapy technique
The radiation therapy parameters used for these patients
have been detailed previously [13]. In general, patients
with primary tumor not encroaching on the cSMG and
without contralateral nodal involvement had cSMG
sparing treatment; in the other patients no attempt was
made to reduce cSMG dose. When possible, bilateral
parotid glands were spared to achieve mean dose <
24 Gy. In order to reduce larynx dose, a split field tech-
nique was used with a matched low-neck en face field
with a larynx block. No specific attempt was made to
spare the pharyngeal constrictor muscles, though there
was an IMRT avoidance structure consisting of the oral
cavity/oropharynx outside of the PTV.
A simultaneous integrated boost method was used.
The highest risk target volume (PTV1) was generally
prescribed 70 Gy in 33 fractions; the intermediate and
low risk subclinical volumes (PTV2 and PTV3) received
62.7 and 57 Gy, respectively.
Analysis
The primary endpoint was time from end of radiation
treatment to freedom from PEG tube dependence. Pa-
tients who never required gastrostomy tube were scored
as achieving the endpoint at time 0. The Kaplan-Meier
method was used to estimate time to PEG tube removal.
Patients were censored at time of last follow-up or
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death. Impact of clinical and dosimetric factors on this
endpoint was assessed using univariate and multivariate
Cox proportional hazards regression.
The secondary endpoint was presence/absence of grade
≥2 late (6 months or more after treatment completion)
observer-rated dysphagia as defined by the Common
Terminology Criteria for Adverse Events (CTCAE)
version 4 [19]. Univariate and multivariate logistic regres-
sion was used to identify patient factors associated with
the outcome. For multivariate analysis of both endpoints,
only covariates with significant p values (p < 0.05) on
univariate analysis were included due to sample size
limitations.
Normal structures, including salivary glands and
swallowing structures, were contoured for the study by
one physician (M.G.) using established guidelines [20].
To improve the uniformity and efficiency of segmenta-
tion, atlas-based contouring was used in MIM version 6
(MIM Software, Cleveland, Ohio, USA). Contours were
drawn on five patients’ CTs and propagated to the rest
of the patients using deformable registration. Contours
were then manually edited to ensure consistency and
accuracy.
For the dosimetric analysis, we included the swallow-
ing structures found to be significantly correlated with
dysphagia in prior studies: the superior, middle, and
inferior constrictor muscles, cricopharyngeal muscle,
esophageal inlet muscles, and glottic/supraglottic larynx
[1, 3, 5]. We also included the salivary structures: cSMG,
parotid glands, and oral cavity (surrogate for minor sal-
ivary glands). For SMG dose, only the contralateral gland
was used since the ipsilateral gland always overlapped
the high dose planning target volume and would not be
expected to have preserved function after treatment. For
parotid gland dose, the mean of the two parotid gland
doses was used since both parotid glands were usually
spared and had similar doses. For all structures, only
mean dose was used, because for both swallowing struc-
tures and salivary glands mean dose has been found to
be highly predictive of patient outcomes [3, 21].
Differences in cSMG dose between patients with
various clinical characteristics were assessed using the
Wilcoxon rank-sum test. Statistical calculations were done
with R software, version 3 (University of Auckland).
Results
Patients and treatments
Sixty-nine patients treated between Dec. 2007 and Feb.
2014 met the inclusion criteria. Patient characteristics
are listed in Table 1. Almost all patients had stage IV
disease (91%) and received concurrent systemic therapy
(97%). The most common systemic therapy was high-
dose cisplatin (n = 55).
Dose to the primary tumor ranged from 66 to 72 Gy;
64 of 69 patients received a dose of 69.96 Gy in 33
fractions. Normal structure doses are listed in Table 2.
In forty-three patients there was an IMRT objective for
the cSMG. No patient had an IMRT objective for the





























Table 2 Doses received by normal structures
Structure Mean dose in Gy (range)
Contralateral submandibular gland 45.23 (18.16–74.24)
Parotid glands (bilateral) 32.50 (18.90–50.92)
Superior pharyngeal constrictor 61.05 (39.54–70.85)
Middle pharyngeal constrictor 62.74 (41.57–72.08)
Inferior pharyngeal constrictor 41.83 (21.90–70.04)
Esophageal inlet muscles 36.37 (10.23–62.91)
Cricopharyngeal muscle 30.85 (9.86–69.08)
Glottic/supraglottic larynx 46.70 (23.91–69.89)
Oral cavity 41.41 (17.37–72.00)
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ipsilateral SMG. Thirty-nine patients (57%) had cSMG
mean dose < 50 Gy, a level which has been shown to pre-
dict preservation of gland function [21]. We examined
whether baseline patient/tumor factors were associated
with ability to perform cSMG sparing. Patients with bilat-
eral nodal disease had higher cSMG doses than others
(mean 59.3 vs. 36.7 Gy, p < 0.0001). Tumor stage (T1-3 vs.
T4) and primary site (base of tongue vs. other) were not
significantly associated with cSMG dose.
Toxicity outcomes
Median follow-up was 27 months (range 7–78 months).
Consistent with the inclusion criteria, no patient suffered
disease recurrence. Two patients are deceased; cause of
death was endocarditis in one and unknown in the other.
Fifty-eight patients (84%) had a gastrostomy tube
placed prior to or during radiation therapy. Seventy-nine
percent of these were placed before or during the first
week of treatment, consistent with our department pol-
icy of prophylactic feeding tube placement for patients
receiving chemoradiation. No patient had a feeding tube
placed after completion of radiation therapy. In patients
with a gastrostomy tube placed, median time to tube
removal was 3.2 months. Gastrostomy tube dependence
rate was 17% six months after treatment and 4% at
twelve months. Two patients were tube dependent at
last follow-up, 11 and 37 months after treatment.
Predictors of time to freedom from PEG dependence
were examined using Cox proportional hazards regres-
sion (Table 3). On univariate analysis, the strongest
predictor was cSMG dose (HR 0.97 per Gy, p < 0.0001).
Other significant predictors were dose to the superior
and middle pharyngeal constrictors, esophageal inlet
muscles, larynx, and oral cavity. Parotid dose was not
significant on any analysis. On multivariate analysis,
cSMG dose was still the strongest predictor of this
endpoint (HR 0.98 per Gy, p = 0.052). Median cSMG
dose was 42.3 Gy. Patients with cSMG dose less than
median (n = 34) had significantly shorter time to free-
dom from PEG tube dependence: median 1.9 vs.
3.5 months, p < 0.0001 by log-rank test (Fig. 1). At
6 months, only 3% (95% CI 0.4–20.2%) of patients with
cSMG dose less than median were PEG tube dependent,
versus 31% (95% CI 19.3–51.3%) of those with cSMG
dose greater than median (p = 0.002). None of the pa-
tients with cSMG dose less than median were PEG tube
dependent at 12 months.
The distribution of observer-rated late dysphagia (worst
grade six months or later after treatment, CTCAE version
4) was: grade 0: 44 patients; grade 1: 10 patients; grade 2:
6 patients; grade 3: 9 patients. We examined predictors of
late grade ≥2 dysphagia, defined as symptomatic and al-
tered eating/swallowing (Table 4). On univariate analysis,
cSMG dose was the strongest predictor of late dysphagia
(OR 1.06 per Gy, p = 0.004). Other significant predictors
were T4 vs. T1-3 tumor stage, bilateral nodal disease, su-
perior constrictor dose, and oral cavity dose. On multivari-
ate analysis, the only significant predictor of late
dysphagia was T4 tumor stage (OR 4.60, p = 0.04).
Thirty-nine patients (57%) had grade ≥2 observer-
rated late xerostomia. Consistent with our prior report,
patients with higher cSMG dose were more prone to
grade ≥2 late xerostomia (OR 1.05 per Gy, p = 0.002)
[13]. Oral cavity dose was also associated with late xer-
ostomia (OR 1.05 per Gy, p = 0.05), but parotid gland
dose was not (p = 0.51). Observer-rated late dysphagia
and xerostomia were modestly correlated, with a phi
coefficient of 0.32, p = 0.02 by the chi-square test.
Table 3 Predictors of time to freedom from PEG tube dependence (Cox proportional hazards model). Lower hazard ratio indicates
later PEG tube removal
Variable (mean doses in Gy) Univariate Multivariate
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Contralateral submandibular gland dose 0.97 (0.95–0.98) <0.0001 0.98 (0.95–1.00) 0.052
Middle pharyngeal constrictor dose 0.92 (0.88–0.96) 0.0002 0.95 (0.89–1.02) 0.18
Superior pharyngeal constrictor dose 0.95 (0.92–0.98) 0.003 0.98 (0.93–1.03) 0.38
Glottic/supraglottic larynx dose 0.97 (0.94–0.99) 0.007 1.02 (0.98–1.07) 0.40
Esophageal inlet muscles dose 0.98 (0.97–1.00) 0.03 0.99 (0.97–1.01) 0.39
Oral cavity dose 0.97 (0.95–0.99) 0.03 1.00 (0.97–1.04) 0.86
Inferior pharyngeal constrictor dose 0.98 (0.96–1.00) 0.09
T4 tumor stage 0.69 (0.42–1.15) 0.16
Parotid glands mean dose 0.98 (0.94–1.02) 0.24
Bilateral nodal involvement 0.77 (0.47–1.27) 0.31
Cricopharyngeal muscle dose 0.99 (0.97–1.01) 0.34
Age 1.00 (0.97–1.03) 0.96
Statistically significant values are given in bold
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Discussion
We examined the influence of clinical and dosimetric
factors on post-treatment PEG dependence in patients
with locally advanced oropharynx cancer. cSMG dose
was the strongest predictor of time to freedom from
PEG tube dependence on both univariate and multivari-
ate analysis. Patients with cSMG dose less than median
(42 Gy) had a 3% rate of PEG tube dependence at
6 months and 0% at 12 months. To our knowledge, this
is the first report of an objectively measured dysphagia
related outcome, i.e., post treatment PEG dependence,
after cSMG sparing bilateral neck IMRT.
Most studies correlating radiation dose to pharyngeal
constrictor muscles and other swallowing-related organs
(larynx, and esophageal inlet) did not include the salivary
glands in their models of dysphagia [3, 6, 7]. During the
process of swallowing a food bolus, in addition to the
neuro-muscular structures involved, an optimal volume
and viscosity of saliva, and adequate lubrication are
necessary [8, 15–18]. While parotid derived stimulated
saliva contributes to the volume of saliva, SMG derived
saliva rich in mucins provides the viscosity and lubrica-
tion needed for swallowing of foods such as dry solids
[15]. A prospective study of 93 patients treated with
radiation therapy showed that post-treatment patient-
reported xerostomia grade was a strong predictor of dys-
phagia grade [9]. Thus, it is plausible that minimizing
xerostomia, by preserving the function of the salivary
glands in addition to sparing the muscular swallowing
structures, could reduce post-treatment dysphagia and
PEG dependence.
Our analysis suggests that sparing the cSMG could be
an important factor in minimizing detriment to the
swallowing process. This is also supported by a study of
354 patients with mostly oropharynx and larynx primar-
ies showing that SMG doses were significant predictors
of post-treatment swallowing dysfunction on univariate
analysis [5]. While parotid glands were routinely spared
(in addition to cSMG) in our cohort, sparing the parotid
glands alone is unlikely to improve swallowing function
as parotid saliva is watery and lacks mucins [12].
The two endpoints in this study (freedom from gastros-
tomy tube dependence after treatment, and late observer-
rated late dysphagia) have both been commonly used as
indicators of dysphagia after radiation therapy [2, 4, 22].
The results for the two endpoints differed somewhat.
While cSMG dose was predictive of both endpoints on
univariate analysis, on multivariate analysis, cSMG dose
was a strong predictor of the objective gastrostomy tube
endpoint but not observer-rated dysphagia (p = 0.052,
0.29, respectively). The feeding tube endpoint may be
more relevant to patients, for a few reasons. First, duration
Fig. 1 Freedom from PEG tube dependence by mean contralateral
submandibular gland dose greater or less than median
Table 4 Predictors of grade ≥2 late observer-rated dysphagia (logistic regression)
Variable (mean doses in Gy) Univariate Multivariate
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Contralateral submandibular gland dose 1.06 (1.02–1.10) 0.004 1.03 (0.98–1.09) 0.29
T4 tumor stage 5.99 (1.77–24.18) 0.006 4.60 (1.17–21.16) 0.04
Superior pharyngeal constrictor dose 1.27 (1.09–1.56) 0.009 1.15 (0.98–1.42) 0.12
Oral cavity dose 1.08 (1.01–1.16) 0.03 1.02 (0.94–1.12) 0.62
Bilateral nodal involvement 3.26 (1.02–11.18) 0.05 1.45 (0.28–7.56) 0.65
Glottic/supraglottic larynx dose 1.06 (1.00–1.12) 0.06
Parotid glands mean dose 1.06 (0.99–1.15) 0.11
Inferior pharyngeal constrictor dose 1.04 (0.99–1.09) 0.13
Middle pharyngeal constrictor dose 1.08 (0.98–1.21) 0.15
Cricopharyngeal muscle dose 1.02 (0.98–1.07) 0.35
Age 1.02 (0.95–1.10) 0.56
Esophageal inlet muscles dose 1.01 (0.97–1.05) 0.63
Statistically significant values are given in bold
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of feeding tube requirement correlates with reduced qual-
ity of life related to late dysphagia. In a study of head and
neck cancer patients one year after treatment, having a
feeding tube present at one year was associated with
reduced quality of life in nine of twelve subscales [23].
Our patients’ 4% PEG tube dependence rate at 12 months
is similar to the 1% rate reported in the constrictor
sparing trial [2] and less than the 9% rate reported among
stage III-IV patients receiving chemoradiation in a multi-
institutional study [4].
Second, observer-rated dysphagia is a subjective
endpoint and is known to correlate poorly with patient-
reported dysphagia [24]. For instance, in a recent
prospective study only 1% of patients had grade 2 or worse
observer-scored dysphagia 24 months after radiation ther-
apy, compared to over 50% of patients reporting dysphagia
at the same time point [9].
An interesting issue could be the tradeoff between
cSMG sparing and pharyngeal constrictor sparing. The
submandibular glands are located at a similar craniocau-
dal location as the middle pharyngeal constrictor muscle
(Fig. 2). A potential concern is that by aggressively
sparing the cSMG instead of prioritizing pharyngeal
constrictor sparing, the dose to swallowing muscles
could increase, worsening dysphagia. A crude compari-
son shows that our patients’ swallowing structure doses
are similar to those in a trial of constrictor muscle sparing
IMRT in which the mean constrictor dose was 58 Gy, the
mean larynx dose was 48 Gy, and the mean esophageal in-
let dose was 34 Gy [2]. This suggests that cSMG sparing
in our series did not overly increase dose to the swallow-
ing structures, as we routinely spared the uninvolved oral
cavity and oropharynx.
The main limitation of this study is the non-randomized
nature of the cSMG sparing treatment, raising the possibil-
ity of bias and unmeasured confounders. Patients without
bilateral nodal involvement were more likely to have cSMG
sparing; nodal stage has been shown in some other series
to be a predictor of post-treatment dysphagia [4]. In the
present study, bilateral nodal disease was not a significant
predictor of gastrostomy tube dependence and was not in-
cluded in the multivariate regression. The lack of patient-
reported quality of life outcomes is another limitation.
Conclusions
This hypothesis-generating study shows that cSMG
sparing radiotherapy may reduce post-treatment PEG
dependence and dysphagia. We are currently conducting
a prospective quality of life study to learn whether
cSMG sparing is associated with improvement in
patient-reported outcomes.
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